logo
  •  

What research projects have been supported?

Research Supported

Year Research Group Project Title
2017 Australian Advanced School of Medicine Macquarie University Prof Gilles Guillemin Re-educating” immune cells as a combination therapy to limit breast cancer metastasis Tumours alter biochemical pathways to reduce immune response and so spread (metastasise). One such pathway is the kynurenine pathway (KP), a biochemical pathway that synthesizes the vital coenzyme factor for daily cell maintenance. This pathway is often elevated in patients with invasive breast cancer and frequently associated with local lymph node metastasis. This proposal will examine if inhibition of the KP will provide an effective therapy to limit metastasis and/or relapse.
2016 Department of Pathology University of Melbourne Prof Melissa Southey High Risk Genes for Lobular Breast Cancer The project is applying whole genome sequencing to DNA extracted from blood corresponding to highly selected invasive lobular breast cancer cases to identify high risk genes for lobular breast cancer. Material for this study has been contributed from a number of research resources including the ABCTB that has provided early-onset (diagnosed under the age of 40 years) cases of invasive lobular breast cancer.
2016 Hunter Medical Research Institute University of Newcastle Dr Michelle Wong-Brown Analysis of tumours from women with BRCA1 methylation in peripheral blood to assess whether tumour morphology is BRCA1-like Constitutional methylation refers to the presence of aberrant methylation (epimutation) of a given gene through multiple normal tissues of the body. In some cases, constitutional methylation may be mosaic, i.e not all cells in affected normal tissues are methylated. Constitutional methylation was shown to occur in breast cancer, despite previous reports and unpublished opinion to the contrary. This was the consequence of our focus on sensitive and reliable DNA methylation detection methodology and our hypothesis that constitutional methylation of BRCA1 would lead to BRCA1 methylationdriven tumours resulting in a phenocopy of BRCA1 mutation-driven tumours.
2016 Children's Hospital Westmead University of Sydney A/Prof Sandra Cooper Myoferlin cleavage – a new marker for metastatic breast cancer? This project will contribute to understand the function of myoferlin in breast cancer, which could lead to new treatment opportunities in the future. After the completion of the pilot study we are aiming to perform a full comprehensive study with a larger sample size.
2016 Southern Cross GeoScience Department Southern Cross University Dr Renaud Joannes-Boyau Stages of trace element scavenging by invasive and in-situ ductal carcinoma Recent studies have shown that certain types of tumors are scavenging metals (e.g. Cu, Zn) to a higher rate than healthy surrounding tissues. Mechanisms leading to higher concentration are not completely understood yet, but certainly play a role in the development of tumors. In this pilot study we would like to investigate the possibility that metal concentration varies depending on the tumors development stage.
2016 Hunter Medical Research Institute University of Newcastle Dr Kelly Avery-Kiejda Is the p53 polymorphism rs17878362 associated with the risk of developing triple-negative breast cancer? We have shown that an alternatively spliced variant of p53, ?40p53, is highly expressed in breast cancer with its highest levels in TNBC. We have also shown that the p53 polymorphism, rs17878362, which alters splicing to increase p53, is associated with low ?40p53:p53 in breast cancer. The exact relationship of the rs17878362 polymorphism to breast cancer risk is variable between studies and no subtype specificity has been reported. Given our data on high ?40p53:p53 ratios in TNBC and the relationship between ?40p53:p53 and rs17878362, this study will examine if rs17878362 is associated with the risk of developing TNBC
2016 Breast Pathology University of Queensland Centre for Clinical Research Dr Peter Simpson Defining the genomic and therapeutic landscape of familial breast cancer Cancer develops from normal cells following the failure of DNA repair processes and the subsequent accumulation of mutations to the DNA. Here we aim to perform whole genome sequencing in order to characterise the types of mutations that occur in familial breast tumours. The identification of specific mutations or altered pathways that drive this process is likely to provide important insights into how cancer develops and how it can be treated.
2015 School of Biomedical Sciences & Pharmacy University of Newcastle Dr Nicole Verrills PPP2R2A as a prognostic biomarker This project aims to establish a new biomarker for disease outcome in a subset of breast cancer patients who currently respond poorly to standard therapies. Using tissues from the ABTB we aim to show that our novel biomarker distinguishes those patients at diagnosis who are most likely to respond well to standard therapy, versus those who will not. Importantly, we believe that those patients with evidence of this biomarker will be sensitive to a special type of chemotherapy not currently offered for these patients, and that introduction of this therapy will improve their survival.
2015 Westmead Institute for Medical Research Universtiy of Sydney Prof Anna de Fazio Essential clinical annotation for NSW Biobanks through data integration with clinical and administrative datasets – a pilot study In this pilot study, we aim to investigate the feasibility, practicality and utility of linking the clinical data annotated to banked cancer biospecimens with State administrative datasets. Having comprehensive and accurate clinical information is essential in achieving the full research potential from banked biospecimens, yet this information can be labour-intensive and costly to obtain for many biobanks. We will evaluate whether the clinical information currently collected and held by the ABCTB can be improved, in terms of completeness and accuracy, by linking to datasets such as the NSW Admitted Patients Data Collection, or the NSW Cancer Registries.
2015 Kolling Institute Universtiy of Sydney Dr Aleksandra Ochknik Preclinical modelling of new therapies for treatment resistant cancers Single-agent therapies are not effective for all cancers and combination therapies that can overcome resistance are essential. Oestrogen receptor (ER) and human epidermal receptor (HER2) negative breast cancer currently relies on cytotoxic chemotherapy with low success rates. Despite advances using HER2-targeted therapies, the high rate of therapy-resistance is an ongoing concern. The aim of this project is to examine the contribution of the oncogenic sphingosine kinase (SphK) and insulin-like growth factor (IGF1R) signalling pathways in therapy-resistant breast cancers using breast tumour patient tissue samples. A successful outcome would lead to development of novel breast cancer combination therapies.
2015 Peter MacCallum Cancer Centre Monash Universtiy
Dr Kara Britt
Define which cell types within the breast protect against breast cancer
2015 Westmead Institute for Cancer Research University of Sydney
Prof Anna DeFazio & Prof Christine Clarke
Essential clinical annotation for NSW Biobanks through data integration with clinical and administrative datasets – a pilot study
2014 The Canberra Hospital
Dr Yada Kanjanapan
Benefit of adjuvant trastuzumab with chemotherapy in small (<1cm) node-negative HER 2 positive breast cancer
2014 Triple Negative Breast Cancer Consortium (TNBCC) Mayo Clinic, Rochester, MN, USA.
Prof. Fergus J. Couch
OncoArray Study
2014 Australian Breast Cancer Tissue Bank.
Prof Jane Dahlstrom
Investigation into the Use of a Digital Image Analysis Tool for Histological Assessment of Biobank Tissue Specimens
2013 St John of God Hospital Subiaco Western Australia.
Dr Libby Thomas
Investigation of FOXP3 and RANKL in tumour-infiltrating T cells and diagnostic marker discovery in locally-advanced and metastatic breast cancer.
2013 Bone Research Program ANZAC Research Institute,University of Sydney.
A/Prof Colin R Dunstan
The Vitamin D Receptor Regulates Breast Cancer Growth and Malignant Potential: A Novel Cytoplasmic F
2013 Centre for Information-Based Medicine Hunter Medical Research Institute (HMRI)John Hunter Hospital, Newcastle.
Prof Rodney Scott
Epigenetics and breast cancer biomarkers
2013 Breast Cancer Association Consortium(BCAC) Hunter Medical Research Institute (HMRI) John Hunter Hospital, Newcastle.
Prof Rodney Scott
OncoArray Study
2012 Kolling Institute, Sydney.
Dr Efty Stavrou
Molecular subtype breast cancer in the ABCTB
2012 School of Surgery EII Medical Centre The University of Western Australia.
Professor Christobel Saunders
Targeting Breast Cancer Recurrence through Epithelial Mesenchymal Plasticity
2012 Kolling Institute, Sydney.
Dr Efty Stavrou
Molecular subtype breast cancer in the ABCTB
2011 Westmead Millenium Institute Sydney.
Dr. Heidi Hilton
The impact of aberrant progesterone signalling on lineage specification during early malignant transformation
2011 Breast Pathology University of Queensland Centre for Clinical Research.
Dr. Peter Simpson
Expression Analyses of Invasive Lobular Carcinomas.
2011 John Hunter Hospital, Newcastle.
Mrs Katherine Bolton
Role of Tandem Repeats on the Risk of Breast Cancer
2011 Department of Immunology and Translational Research The Canberra Hospital Assoc.
Prof. Matthew Cook
Candidate miRNA in breast cancer.
2011 School of Biomedical Sciences & Pharmacy University of Newcastle.
Dr Judith Weidenhofer
Investigation of the control of tetraspanin expression in breast cancer: implications for biomarker discovery.
2011 Peter MacCallum Cancer Centre, Melbourne.
A/Prof Ian G Campbell
High resolution genome-wide genomic analysis of breast cancer precursor lesions to identify markers
2011 Centre for Information-Based Medicine Hunter Medical Research Institute (HMRI) John Hunter Hospital, Newcastle
Prof Rodney Scott
Genetic Variation in Breast Cancer
2010 Medical Oncology Westmead Hospital, Sydney.
Dr Rosemary Balleine
Molecular grade as prognostic indicator in invasive breast cancer.
2010 Hunter Area Pathology Service John Hunter Hospital, Newcastle.
Prof. Rodney Scott
The role of p53 isoforms in breast cancer progression
2010 Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital, Sydney.
Dr. Sandra O'Toole
Molecular biomarkers of prognosis and treatment response in breast cancer.
2010 Hormones and Cancer Group, Kolling Institute.
Prof Robert Baxter
Discovery of serum biomarkers for breast cancer
2010 Australian Centre for Microscopy & Microanalysis The University of Sydney.
Dr. Lillian Soon.
Characterisation of invasive tumour cells
2009 Cancer Genetics Kolling Institute, Sydney.
Dr Patsy Soon
The role of microRNAs in the progression of ductal carcinoma in situ to invasive breast cancer
2009 Mayo Clinic, Rochester, MN, USA.
Prof. Fergus J. Couch
Genetic epidemiology of triple negative breast cancer
2009 Cancer Genetics Kolling Institute, Sydney.
Dr Patsy Soon
Correlation of serum miRNAs in breast cancer patients with clinical parameters
2008 Tumour Progression Group The Garvan Institute.
Dr Alexander Swarbrick
The role of Id1 in breast cancer initiating cells
2008 National Breast Cancer Foundation Collaborative Program.
Project Manager, Dr Elizabeth Kuczek
Identification of nuclear receptor (NR) networks active in breast cancers, to establish new predictive and therapeutic targets in women currently underserved by existing treatments, including young women with ER-PR-, or women with metastatic disease.
2008 Centenary Institute - Vascular Biology Program Tumour Senescence Group.
Dr Matthew Grimshaw
Vascular senescence in breast tumour progression.
2008 Breast Cancer Association Consortium.
Prof. Georgia Chenevix-Trench
Collaborative Oncological Gene- environment study (COGS) - Polymorphisms associated with breast tumour subtypes and outcome
2008 Hormones and Cancer Group Kolling Institute, Sydney.
Prof. Robert Baxter
The use of SELDI-TOF MS for biomarker discovery in breast cancer tissue.